To address the hypothesis that GFAP and NfL show different patterns across inflammatory CNS diseases, we compared their CSF and serum levels between controls, stable (NEDA3) MS patients, active progressive MS patients, and active AE patients. The gene discussed is GFAP; the disease is myeloid sarcoma.